SCHEDULE 13D

Company

Enliven Therapeutics, Inc.

Filed

February 28, 2023

Accession Number

0000947871-23-000250

A Schedule 13D is filed when an investor acquires more than 5% of a company's shares with an intent to influence control. Learn more about SC 13D filings →